Equity Profile

ADMA

ADMA Biologics, Inc.

Health CareBiotechnology$2.1B

Aug5Wed

Pre-Earnings Brief

UpcomingQ2-2026After Close5:00 PM EDT

Company Snapshot

ADMA Biologics, Inc. is a biotechnology company focused on developing and commercializing specialty biologics for the treatment of immune deficiencies and infectious diseases....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health.

N/A

Revenue Growth

Revenue growth reflects the company's ability to expand its market presence and product offerings.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

ADMA Q2-2026 Earnings Preview

Context

Company Snapshot

ADMA Biologics, Inc. is a biotechnology company focused on developing and commercializing specialty biologics for the treatment of immune deficiencies and infectious diseases. With a market cap of $2 billion, it operates in the health care sector, which is increasingly important as demand for innovative medical treatments continues to grow.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

38%

Avg EPS Surprise

+30.88%

Avg Stock Reaction

+0.95%

Last Quarter Recap

In Q1 2026, ADMA reported an EPS of $0.19, showing a stable performance compared to previous quarters. However, the stock experienced a slight decline of 1.66% the following day, indicating mixed investor sentiment.

Management Promises & Guidance

Expectations

Wall Street Expectations

Investors are cautiously optimistic ahead of the earnings report, with expectations that ADMA may continue its trend of beating EPS estimates. However, the lack of analyst estimates adds uncertainty to the outlook.

Bull Case

If ADMA can show strong revenue growth and maintain or exceed its EPS from the previous quarter, it could lead to a positive market reaction.

Bear Case

Conversely, if the company fails to meet expectations or shows signs of declining sales, it could lead to a significant drop in stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be for Q2-2026?

The EPS figure will be crucial in determining whether ADMA continues its trend of beating estimates and how investors react.

How did product sales perform in the last quarter?

Understanding sales performance will provide insight into market demand and the company's growth trajectory.

Edge

What the Street Is Missing

Why consensus could be wrong

The consensus may underestimate ADMA's ability to leverage its existing product pipeline, potentially leading to stronger-than-expected revenue growth.

Supporting Evidence

The company has a history of beating EPS estimates, with a 67% success rate in the last eight quarters.

Options pricing suggests a significant move, indicating that investors are bracing for surprises.

The recent performance trends show a potential for recovery in product sales.

Key Risk

If product sales exceed expectations, it could challenge the current cautious outlook.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance will be closely watched as it could either reinforce or challenge the company's growth narrative.

Bull Confirmed If

An EPS of $0.20 or higher would confirm the bullish outlook and suggest strong operational performance.

Bear Confirmed If

An EPS below $0.15 would indicate potential issues with profitability and market demand.

Pre-Earnings Positioning

Options Market

Implied Move

±26.94%

Historical Avg

±2.8%

Pricing rich

The options market is pricing in a significant potential move in either direction, indicating high uncertainty surrounding the earnings report.

Options are pricing ±26.9% while ADMA has averaged ±2.8% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.7%

30d HV

61.6%

Calls (13K)P/C Ratio: 1.16Puts (800)

Edge

Institutional Ownership

Smart-money positioning from the most recent 13F filings.

Top holders adding

Institutional

97.01%

of float

Insider

1.85%

of float

Holders

474

institutions

Top Holders· as of Dec 2025

Blackrock Inc.
36,333,325 sh · $409.1M
15.64%
2.0%

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If ADMA beats expectations, history suggests the stock could rise by around 0.27%, confirming positive investor sentiment.

In-Line / Cautious

A cautious in-line report could lead to muted reactions as investors await further clarity from management commentary.

Miss

If the company misses expectations, history suggests a potential decline of around 3.59%, reflecting investor disappointment.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Management's commentary on product sales and market demand.
2Updates on any new product launches or pipeline developments.
3Guidance on future earnings expectations.
4Insights into competitive positioning within the biotechnology sector.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug3

ONBMO

ON Semiconductor Corporation

PreviewView

Aug3

LBMO

Company Snapshot

ADMA Biologics, Inc. is a biotechnology company focused on developing and commercializing specialty biologics for the treatment of immune deficiencies and infectious diseases....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health.

N/A

Revenue Growth

Revenue growth reflects the company's ability to expand its market presence and product offerings.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

ADMA Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

38%

Avg EPS Surprise

+30.88%

Avg Stock Reaction

+0.95%

Last Quarter Recap

Management Promises & Guidance

Expectations

Wall Street Expectations

Bull Case

If ADMA can show strong revenue growth and maintain or exceed its EPS from the previous quarter, it could lead to a positive market reaction.

Bear Case

Conversely, if the company fails to meet expectations or shows signs of declining sales, it could lead to a significant drop in stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be for Q2-2026?

The EPS figure will be crucial in determining whether ADMA continues its trend of beating estimates and how investors react.

How did product sales perform in the last quarter?

Understanding sales performance will provide insight into market demand and the company's growth trajectory.

Edge

What the Street Is Missing

Why consensus could be wrong

The consensus may underestimate ADMA's ability to leverage its existing product pipeline, potentially leading to stronger-than-expected revenue growth.

Supporting Evidence

The company has a history of beating EPS estimates, with a 67% success rate in the last eight quarters.

Options pricing suggests a significant move, indicating that investors are bracing for surprises.

The recent performance trends show a potential for recovery in product sales.

Key Risk

If product sales exceed expectations, it could challenge the current cautious outlook.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance will be closely watched as it could either reinforce or challenge the company's growth narrative.

Bull Confirmed If

An EPS of $0.20 or higher would confirm the bullish outlook and suggest strong operational performance.

Bear Confirmed If

An EPS below $0.15 would indicate potential issues with profitability and market demand.

Pre-Earnings Positioning

Options Market

Implied Move

±26.94%

Historical Avg

±2.8%

Pricing rich

The options market is pricing in a significant potential move in either direction, indicating high uncertainty surrounding the earnings report.

Options are pricing ±26.9% while ADMA has averaged ±2.8% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.7%

30d HV

61.6%

Calls (13K)P/C Ratio: 1.16Puts (800)

Edge

Institutional Ownership

Smart-money positioning from the most recent 13F filings.

Top holders adding

Institutional

97.01%

of float

Insider

1.85%

of float

Holders

474

institutions

Top Holders· as of Dec 2025

Blackrock Inc.
36,333,325 sh · $409.1M
15.64%
2.0%

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If ADMA beats expectations, history suggests the stock could rise by around 0.27%, confirming positive investor sentiment.

In-Line / Cautious

A cautious in-line report could lead to muted reactions as investors await further clarity from management commentary.

Miss

If the company misses expectations, history suggests a potential decline of around 3.59%, reflecting investor disappointment.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Management's commentary on product sales and market demand.
2Updates on any new product launches or pipeline developments.
3Guidance on future earnings expectations.
4Insights into competitive positioning within the biotechnology sector.